Recombinant Leishmania Tarentolae Encoding the HPV Type 16 E7 gene in Tumor Mice Model

• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2) , 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Chen CH , WangTL, HungCF, PardollDM, WuTC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine18(19) , 2015–2022 (2000).
   PubMed Web of Science ®Google Scholar
• Roden RB , LingM, WuTC. Vaccination to prevent and treat cervical cancer. Hum. Pathol.35(8) , 971–982 (2004).
   PubMed Web of Science ®Google Scholar
• Munger K , PhelpsWC, BubbV, HowleyPM, SchlegelR. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol.63(10) , 4417–4421 (1989).
   PubMed Web of Science ®Google Scholar
• Londono LP , ChatfieldS, TindleRW et al. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine 14(6) , 545–552 (1996).
   PubMed Web of Science ®Google Scholar
• Hudson JB , BedellMA, MccanceDJ, LaiminisLA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol.64(2) , 519–526 (1990).
   PubMed Web of Science ®Google Scholar
• Crook T , MorgensternJP, CrawfordL, BanksL. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J.8(2) , 513–519 (1989).
   PubMed Web of Science ®Google Scholar
• Mahdavi A , MonkBJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist10(7) , 528–538 (2005).
   PubMed Web of Science ®Google Scholar
• Jochmus-Kudielka I , SchneiderA, BraunR et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J. Natl Cancer Inst. 81(22) , 1698–1704 (1989).
   PubMedGoogle Scholar
• Bolhassani A , ZahedifardF, TaghikhaniM, RafatiS. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine26(26) , 3362–3370 (2008).
   PubMed Web of Science ®Google Scholar
• Ressing ME , SetteA, BrandtRM et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154(11) , 5934–5943 (1995).
   PubMed Web of Science ®Google Scholar
• Tindle RW , FrazerIH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr. Top Microbiol. Immunol.186 , 217–253 (1994).
   PubMedGoogle Scholar
• Lamikanra A , PanZK, IsaacsSN, WuTC, PatersonY. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+T-cell responses that home to the tumor site. J. Virol.75(20) , 9654–9664 (2001).
   PubMed Web of Science ®Google Scholar
• Einstein MH , BaronM, LevinMJ et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum. Vaccin. 7(12) , 1343–1358 (2011).
   PubMed Web of Science ®Google Scholar
• Paavonen J , JenkinsD, BoschFX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580) , 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Villa LL , CostaRL, PettaCA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6(5) , 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• Karanam B , GambhiraR, PengS et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27(7) , 1040–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Satyaprakash A , CreedR, RavanfarP, MendozaN. Human papillomavirus vaccines. Dermatol. Ther.22(2) , 150–157 (2009).
   PubMed Web of Science ®Google Scholar
• De Jong A , O‘NeillT, KhanAY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20(29–30) , 3456–3464 (2002).
   PubMed Web of Science ®Google Scholar
• Trimble C , LinCT, HungCF et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21(25–26) , 4036–4042 (2003).
   PubMed Web of Science ®Google Scholar
• Van Der Burg SH , KwappenbergKM, O‘NeillT et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19(27) , 3652–3660 (2001).
   PubMed Web of Science ®Google Scholar
• Sewell DA , DouvenD, PanZK, RodriguezA, PatersonY. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch. Otolaryngol. Head Neck Surg.130(1) , 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper LZ , GilesJP, KrugmanS. Clinical trial of live attenuated rubella virus vaccine, HPV-77 strain. Am. J. Dis. Child.115(6) , 655–657 (1968).
   PubMedGoogle Scholar
• Meyer HM Jr, Parkman PD, Hobbins TE, Ennis FA. Clinical studies with experimental live rubella virus vaccine (strain HPV-77). Evaluation of vaccine-induced immunity. Am. J. Dis. Child.115(6) , 648–654 (1968).
   PubMedGoogle Scholar
• Krul MR , TijhaarEJ, KleijneJA et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol. Immunother. 43(1) , 44–48 (1996).
   PubMed Web of Science ®Google Scholar
• Borysiewicz LK , FianderA, NimakoM et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347(9014) , 1523–1527 (1996).
   PubMed Web of Science ®Google Scholar
• Christensen ND , HanR, CladelNM, PickelMD. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob. Agents Chemother.45(4) , 1201–1209 (2001).
   PubMed Web of Science ®Google Scholar
• Wilkins J , LeedomJM, PortnoyB, SalvatoreMA. Reinfection with rubella virus despite live vaccine induced immunity. Trials of HPV-77 and HPV-80 live rubella virus vaccines and subsequent artificial and natural challenge studies. Am. J. Dis. Child.118(2) , 275–294 (1969).
   PubMedGoogle Scholar
• Singh R , PatersonY. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev. Vaccines5(4) , 541–552 (2006).
   PubMed Web of Science ®Google Scholar
• Maciag PC , RadulovicS, RothmanJ. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine27(30) , 3975–3983 (2009).
   PubMed Web of Science ®Google Scholar
• Breton M , TremblayMJ, OuelletteM, PapadopoulouB. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun.73(10) , 6372–6382 (2005).
   PubMed Web of Science ®Google Scholar
• Breton M , ZhaoC, OuelletteM, TremblayMJ, PapadopoulouB. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J. Gen. Virol.88(Pt 1) , 217–225 (2007).
   PubMed Web of Science ®Google Scholar
• Mizbani A , TaheriT, ZahedifardF et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28(1) , 53–62 (2009).
   PubMed Web of Science ®Google Scholar
• Papadopoulou B , RoyG, OuelletteM. A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J.11(10) , 3601–3608 (1992).
   PubMed Web of Science ®Google Scholar
• Daneshvar H , CoombsGH, HaganP, PhillipsRS. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis.187(10) , 1662–1668 (2003).
   PubMed Web of Science ®Google Scholar
• Mohit E , BolhassaniA, ZahedifardF, TaslimiY, RafatiS. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model. Scand. J. Immunol.75(1) , 27–37 (2012).
   PubMed Web of Science ®Google Scholar
• Naito S , van Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res.46(8) , 4109–4115 (1986).
   PubMed Web of Science ®Google Scholar
• Toes RE , HoebenRC, Van Der Voort EI et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl Acad. Sci. USA94(26) , 14660–14665 (1997).
   PubMed Web of Science ®Google Scholar
• Adachi K , KawanaK, YokoyamaT et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28(16) , 2810–2817 (2010).
   PubMed Web of Science ®Google Scholar
• Snapper CM , PaulWE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science236(4804) , 944–947 (1987).
   PubMed Web of Science ®Google Scholar
• Ferrick DA , SchrenzelMD, MulvaniaT, HsiehB, FerlinWG, LepperH. Differential production of interferon-γ and interleukin-4 in response to Th1- and Th2-stimulating pathogens by γδ T cells in vivo. Nature373(6511) , 255–257 (1995).
   PubMed Web of Science ®Google Scholar
• Warren HS , VogelFR, ChedidLA. Current status of immunological adjuvants. Annu. Rev. Immunol.4 , 369–388 (1986).
   PubMed Web of Science ®Google Scholar
• Brown DM , FisherTL, WeiC, FrelingerJG, LordEM. Tumours can act as adjuvants for humoral immunity. Immunology102(4) , 486–497 (2001).
   PubMed Web of Science ®Google Scholar
• Lu Z , GhazizadehS. Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy. Mol. Ther.15(5) , 954–961 (2007).
   PubMed Web of Science ®Google Scholar
• Andreakos E , WilliamsRO, WalesJ, FoxwellBM, FeldmannM. Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvant. Proc. Natl Acad. Sci. USA103(39) , 14459–14464 (2006).
   PubMed Web of Science ®Google Scholar
• Medina-Bolivar F , WrightR, FunkV et al. A non-toxic lectin for antigen delivery of plant-based mucosal vaccines. Vaccine 21(9–10) , 997–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Stripecke R , Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther.6(7) , 1305–1312 (1999).
   PubMed Web of Science ®Google Scholar
• Lin KY , GuarnieriFG, Staveley-O‘CarrollKF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56(1) , 21–26 (1996).
   PubMed Web of Science ®Google Scholar
• Chu NR , WuHB, WuT, BouxLJ, SiegelMI, MizzenLA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette–Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol.121(2) , 216–225 (2000).
   PubMed Web of Science ®Google Scholar
• Chen CH , WangTL, HungCF et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60(4) , 1035–1042 (2000).
   PubMed Web of Science ®Google Scholar
• Suzue K , ZhouX, EisenHN, YoungRA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl Acad. Sci. USA94(24) , 13146–13151 (1997).
   PubMed Web of Science ®Google Scholar
• Yan W , ChenWC, LiuZ, HuangL. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Cytokine52(3) , 238–244 (2010).
   PubMed Web of Science ®Google Scholar
• Schwarz TF , LeoO. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol. Oncol.110(3 Suppl. 1) , S1–S10 (2008).
   PubMed Web of Science ®Google Scholar
• Bermudez-Humaran LG , Cortes-PerezNG, LefevreF et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol. 175(11) , 7297–7302 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart TJ , DraneD, MalliarosJ et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 22(27–28) , 3738–3743 (2004).
   PubMed Web of Science ®Google Scholar
• Hsieh CJ , KimTW, HungCF et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22(29–30) , 3993–4001 (2004).
   PubMed Web of Science ®Google Scholar
• Vazquez Blomquist D , GreenP, LaidlawSM, SkinnerMA, BorrowP, DuarteCA. Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide. Viral. Immunol.15(2) , 337–356 (2002).
   PubMed Web of Science ®Google Scholar
• Decrausaz L , RevazV, BobstM, CorthesyB, RomeroP, Nardelli-HaefligerD. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int. J. Cancer126(10) , 2469–2478 (2010).
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D , RomeroP, JichlinskiP. What is the influence of vaccination‘s routes on the regression of tumors located at mucosal sites? Oncoimmunology1(2) , 242–243 (2012).
   PubMed Web of Science ®Google Scholar
• Decrausaz L , Domingos-PereiraS, DucM et al. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int. J. Cancer 129(3) , 762–772 (2011).
   PubMed Web of Science ®Google Scholar
• Di Bonito P , GrassoF, MochiS et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395(1) , 45–55 (2009).
   PubMed Web of Science ®Google Scholar
• Ravindran R , MajiM, AliN. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol. Pharm.9(1) , 59–70 (2012).
   PubMed Web of Science ®Google Scholar
• Swart AM , BurdettS, LedermannJ, MookP, ParmarMK. Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Ann. Oncol.19(4) , 688–695 (2008).
   PubMed Web of Science ®Google Scholar
• Kelley DE , HenryRR, EdelmanSV. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group. Diabetes Care19(11) , 1237–1242 (1996).
   PubMed Web of Science ®Google Scholar

▪ Website

• Jena Bioscience. www.jenabioscience.com
   Google Scholar